HMN 2025: How GLP-1 RA medicines are discovered to be secure and efficient for treating weight problems in adults with psychological sickness

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can result in vital weight reduction and enhance blood sugar {control} in adults with extreme psychological sickness, in addition to having constructive results on temper, well-being, and high quality of life in these each with and with out psychological sickness, in accordance with a scientific assessment of the obtainable proof being offered on the European Congress on Obesity (ECO) in Malaga, Spain (11–14 May).

The work can also be published within the journal Psychoneuroendocrinology.

“Our findings counsel that GLP-1RAs could be simply as secure and efficient in adults with psychological sickness as they’re in mentally wholesome people, considerably lowering psychotropic drug-induced weight acquire and enhancing glucose {control}, whereas defending cardiometabolic well being,” says lead creator Dr. Sigrid Breit from the University of Bern, Switzerland.

“These outcomes are notably essential for individuals with extreme psychological issues who’re thrice extra prone to be dwelling with weight problems than the final inhabitants.”

Mental sicknesses are related to an elevated threat of weight acquire and metabolic issues like weight problems and sort 2 diabetes. Estimates counsel that round 60% of individuals with extreme psychological issues reside with obese or weight problems.

Substantial weight acquire can also be a standard facet impact of many mood-altering medicine (psychotropics), which embody antidepressants and antipsychotics, particularly for people with extreme psychological sicknesses like schizophrenia and main depressive dysfunction who should take their medicines indefinitely to scale back the chance of symptom relapse.

Originally developed to deal with diabetes, GLP-1RAs like liraglutide and semaglutide mimic the motion of a hormone referred to as glucagon-like peptide 1 (GLP-1), which stimulates insulin manufacturing and lowers blood sugar ranges. More just lately, they’ve emerged as efficient therapies for weight problems—slowing digestion, growing emotions of fullness, and lowering starvation.

However, proof for the affect of GLP-1RAs in people with weight problems and psychological sickness is proscribed. There have additionally been issues that these medicines might enhance the chance of suicide and self-harm.

To discover out extra, Swiss researchers systematically reviewed the proof from medical trials and case collection analyzing the protection and the affect of GLP-1RAs on psychotropic drug-induced metabolic issues reminiscent of weight problems and sort 2 diabetes in addition to psychological sickness outcomes from January 1st, 2010 to August thirty first, 2024.

Data have been analyzed for 36 research involving a complete of 25,677 adults (aged 18 or older) from 19 nations. Eighteen research examined the impact of GLP-1RAs on weight reduction, glucose {control} and psychological sickness outcomes in adults with a extreme psychological dysfunction, reminiscent of main depressive dysfunction, bipolar affective dysfunction, schizophrenia spectrum issues, and alcohol use dysfunction.

The different 18 research examined emotional well-being and high quality of life in adults with obese or weight problems however with no historical past of extreme psychological sickness following GLP-1RAs therapy.

Overall, 4 completely different GLP-1RAs have been investigated within the trials—liraglutide (also called Victoza), semaglutide (Ozempic or Wegovy), exenatide (Byetta or Bydureon), and dulaglutide (Trulicity).

The evaluation discovered that therapy with GLP-1RAs led to vital weight reduction and improved glycemic {control} in adults with psychological sickness taking psychotropics.

The best weight reduction was reported in a randomized trial of liraglutide (as much as 3 mg each day). Participants with schizophrenia or schizoaffective dysfunction utilizing this remedy misplaced as much as 5.3kg extra of their beginning weight and lowered their glucose ranges (HbA1c) by 3.6 mmol/mol extra after six months in contrast with contributors taking placebo. Semaglutide (2.4 mg as soon as weekly) brought on weight lack of as much as 15.7% after 68 weeks in sufferers taking antidepressants in contrast with placebo.

No hyperlink with suicidal ideas or conduct

Importantly, the outcomes confirmed that GLP-1RAs weren’t related to a worsening psychological state, suicidal conduct, new psychological sickness diagnoses, or elevated psychiatric admissions.

For instance, evaluation of 4 research on suicidality in adults with bipolar dysfunction, main or bipolar depressive dysfunction or no psychological sickness discovered that liraglutide was not linked to considerably elevated charges of suicidal ideation (having ideas of suicide). Two additional research of exenatide in sufferers with alcohol use dysfunction and liraglutide in bipolar dysfunction discovered no vital distinction in suicidal conduct in contrast with placebo.

Dr. Breit cautions, “Until we have now higher proof, individuals taking GLP-1RAs needs to be fastidiously monitored, particularly these with psychological sickness.”

Beneficial affect on psychological well being

The evaluation additionally discovered that GLP-1RAs had a useful impact on psychological well being in adults with and with out psychological issues. Five research discovered that they have been secure and improved psychological sickness consequence and high quality of life in individuals with schizophrenia spectrum issues, main depressive dysfunction, and bipolar affective dysfunction.

In adults with out psychological sickness, GLP-1RAs demonstrated a superior impact on temper, emotional well-being, and high quality of life in contrast with insulin and different antidiabetic medicine. For instance, a randomized trial in sufferers with sort 2 diabetes discovered that liraglutide (1.2 or 1.8 mg) considerably improved emotional well-being and basic perceived well being in comparison with glimepiride (8 mg each day).

Dr. Breit explains, “GLP-1 RAs might have antidepressant and anti-anxiety results, doubtlessly attributable to their anti-inflammatory and anti-oxidative properties, which may additionally assist cut back neuroinflammation.”

She provides, “This analysis gives much-needed proof in assist of GLP-1RAs to assist safely handle the burden of weight problems in individuals with psychological sickness.

“However, extra information from large-scale randomized trials and longer therapy and follow-up intervals are wanted to determine the long-term efficacy of GLP-1 RAs, in addition to future research exploring whether or not these medicines could be helpful for the direct therapy of psychological well being issues.”

Provided by
European Association for the Study of Obesity